A BSTRACT
Background The recent recognition that coronaryartery stenting has improved the short-and long-term outcomes of patients treated with angioplasty has made it necessary to reevaluate the relative benefits of bypass surgery and percutaneous interventions in patients with multivessel disease.
Methods A total of 1205 patients were randomly assigned to undergo stent implantation or bypass surgery when a cardiac surgeon and an interventional cardiologist agreed that the same extent of revascularization could be achieved by either technique. The primary clinical end point was freedom from major adverse cardiac and cerebrovascular events at one year. The costs of hospital resources used were also determined.
Results At one year, there was no significant difference between the two groups in terms of the rates of death, stroke, or myocardial infarction. Among patients who survived without a stroke or a myocardial infarction, 16.8 percent of those in the stenting group underwent a second revascularization, as compared with 3.5 percent of those in the surgery group. The rate of event-free survival at one year was 73.8 percent among the patients who received stents and 87.8 percent among those who underwent bypass surgery (P<0.001 by the log-rank test). The costs for the initial procedure were $4,212 less for patients assigned to stenting than for those assigned to bypass surgery, but this difference was reduced during follow-up because of the increased need for repeated revascularization; after one year, the net difference in favor of stenting was estimated to be $2,973 per patient.
HE latest worldwide survey of coronary revascularization shows that 583,000 coronary-artery bypass operations were performed in 1995. 1 According to European statistics, the annual rate of use of balloon angioplasty is approximately 739 procedures per million population. 2 Approximately 60 percent of patients treated with balloon angioplasty or bypass surgery have multivessel disease that could be treated by either pro-T cedure. 3 The most appropriate treatment remains a matter of debate. Earlier studies suggested that patients undergoing either procedure have similar outcomes in terms of survival and rates of myocardial infarction, but patients treated with bypass surgery needed fewer additional interventions. 4 However, subsequent improvements in both percutaneous and surgical techniques may now limit the validity of any conclusions that have been drawn from the earlier studies.
Reevaluation may be especially important in the case of angioplasty, since several studies show that coronary stenting necessitates fewer repeated revascularization procedures than does angioplasty without stenting. 5, 6 Although surgery may still be considered more appropriate than conventional balloon angioplasty for multivessel disease, this may not be the case when stent placement is performed in conjunction with balloon angioplasty. 7, 8 Another reason to reevaluate these surgical and percutaneous techniques is the growing concern about the cost of health care. Although stenting may still be less effective than surgery, as indicated by the need for repeated revascularization, its use may result in cost savings. 6, 9, 10 Increasingly, the additional effects of new therapies must be weighed against their costs. [11] [12] [13] Therefore, the Arterial Revascularization Therapies Study was designed to compare not only clinical outcomes, but also the costs to the hospital of resources associated with bypass surgery and stenting and the relative cost effectiveness of the procedures.
METHODS

Study Design
We conducted a randomized trial comparing coronary bypass surgery with percutaneous transluminal coronary angioplasty and stenting. For each patient, entry into the study required agreementtient's quality of life after 30 days and at 1, 3, and 5 years. An extensive description of the study's aims, the selection of patients, the criteria for exclusion, the procedural guidelines, and the administrative structure has been published previously. 14 
Selection of Patients
Patients who had not previously undergone bypass surgery or angioplasty were eligible for coronary revascularization if they had either stable angina pectoris (Canadian Cardiovascular Society class I, II, III, or IV) 15 or unstable angina pectoris (Braunwald class  IB, IC, IIB, IIC, IIIB, or IIIC) 16 or if they had silent ischemia and at least two new lesions that were located in different vessels and territories (not including the left main coronary artery) and that were potentially amenable to stent implantation. Patients gave written informed consent and were randomly assigned to a treatment group over the telephone by the central office of the study.
One major epicardial vessel or side branch with total occlusion could be included and targeted, provided that the occlusion had been present for less than one month (according to the clinical history) and that one other major vessel had clinically significant stenosis that was amenable to stenting. Conventional balloon angioplasty was permitted, as a complementary treatment without stent implantation, in vessels between 1.50 mm and 2.75 mm in diameter if at least two substantial lesions were targeted for stenting. Each patient had to require more than one stent. Decisions to place stents in lesions at bifurcations, in side branches, or in vessels with fresh thrombi, calcifications, very long obstructions (longer than 20 mm), or complex anatomical features were left to the discretion of the operators.
Patients had to have a left ventricular ejection fraction of more than 30 percent, and patients with overt congestive heart failure were excluded. 14, 17 Patients were also excluded if they had a history of a cerebrovascular accident; if they had had transmural myocardial infarction in the previous week; if they had severe hepatic or renal disease, diseased saphenous veins, neutropenia or thrombocytopenia, or an intolerance or contraindication to acetylsalicylic acid or ticlopidine; or if they needed concomitant major surgery (e.g., valve surgery, resection of an aortic or left ventricular aneurysm, carotid endarterectomy, or surgery for an abdominal aortic aneurysm).
End Points
The primary end point was freedom, for 12 months after randomization, from major adverse cardiac or cerebrovascular events, defined as death; stroke, transient ischemic attacks, and reversible ischemic neurologic deficits 14 ; documented nonfatal myocardial infarction; and repeated revascularization by percutaneous intervention or surgery. Deaths from all causes were reported.
In the first seven days after the intervention, a definite diagnosis of myocardial infarction was made if there was documentation of new abnormal Q waves (according to the Minnesota code) 18 and either a ratio of serum creatine kinase MB (CK-MB) isoenzyme to total cardiac enzyme that was greater than 0.1 or a CK-MB value that was five times the upper limit of normal. Serum creatine kinase and CK-MB isoenzyme concentrations were measured 6, 12, and 18 hours after the intervention. Beginning eight days after the intervention (the length of the hospital stay after surgery), either abnormal Q waves or enzymatic changes were sufficient for a diagnosis of myocardial infarction. This two-part method of defining myocardial infarction was used to eliminate the difficulty of diagnosing a myocardial infarction after surgery. 19, 20 A myocardial infarction was confirmed only after the relevant electrocardiograms had been analyzed by the electrocardiographic core laboratory and adjudicated by a clinical-events committee. All revascularization procedures after the initial intervention and the reasons for them were recorded.
The secondary objective of this study was to compare the two treatment strategies at one year with respect to the following: angina status, use of medications, costs, cost effectiveness, and quality of life; a combined end point of death, myocardial infarction, or stroke; and the rates of death, myocardial infarction, stroke, and revascularization procedures. Events were counted from the time of randomization, whereas clinical status was assessed 1 month, 6 months, and 12 months after a planned intervention.
Costs, Efficacy, and Cost Effectiveness
The costs that were considered were the direct medical costs to the hospital per patient, calculated as the number of resource units (therapeutic procedure, diagnostic procedure, or device) used multiplied by the cost per unit. The resources included outpatient visits, hospital days, postoperative intensive care, coronary care, nonintensive and noncoronary care, diagnostic tests (e.g., clinical laboratory tests), therapeutic procedures measured in terms of their duration (e.g., angiography and surgery), materials consumed (e.g., balloons, wires, catheters, and stents used in revascularization), medication, and rehabilitation services. Patients were also given a "passport" so that the same data could be recorded if they were treated at other hospitals. Unit costs were estimated before the data were analyzed and the estimates were based on detailed information provided by the Dijkzigt Hospital, Rotterdam, the Netherlands, as reported previously. 6, 10 *Plus-minus values are means ±SD. †The body-mass index is defined as the weight in kilograms divided by the square of the height in meters. ‡Stable angina was defined according to the system of the Canadian Cardiovascular Society. 15 §Unstable angina was defined according to the system of Braunwald. 16 ¶The vessel territory and the extent of occlusion involved were assessed by an independent angiographic core laboratory. ¿Involvement of a left main coronary artery was a violation of the study protocol. Efficacy was expressed in terms of the primary end point of event-free survival. The balance between costs and efficacy was expressed in terms of the incremental cost-effectiveness ratio, defined as the additional costs per additional year of survival without a major adverse cardiac or cerebrovascular event. Secondary measures of efficacy were assessed by means of the EuroQol questionnaire regarding the quality of life, on which patients grade their general health status. 21 The questionnaire comprises five items -mobility, self-care, usual activity, pain or discomfort, and anxiety or depression -each of which may be rated as "no problem," "moderate problem," or "severe problem." These ratings were then summarized (EuroQol summary) after being weighted to account for differences in the importance of the various items to the patient. 21 The questionnaire also includes a visual-analogue scale (EuroQol thermometer) for patients to use in rating their overall status from 0 ("worst" imaginable health) to 100 ("best" imaginable health).
Statistical Analysis
A total of 600 patients in each of the two groups was required for the study to be able to reject the null hypothesis that at one year the difference in the frequency of major adverse cardiac and cerebrovascular events (event-free survival) in favor of bypass surgery would not exceed 7 percentage points. With the actual sample size, the study achieved a power of 92 percent with the assumption of a two-sided type I error level ( a ) of 0.05.
Continuous variables were estimated as means ±SD and compared with use of Student's unpaired t-test. Fisher's exact test was used for categorical variables with nominal scales and the Wilcoxon or Mann-Whitney rank-sum test for those with ordinal scales. Discrete variables were reported as counts and percentages and were compared in terms of relative risks (for the surgery group versus the stenting group) with 95 percent confidence intervals, calculated according to the formula of Greenland and Robins. 22 All analyses were based on the intention-to-treat principle, and statistical tests were two-tailed.
Event-free survival was estimated by the Kaplan-Meier method, and differences were assessed by means of the log-rank test. A multivariate logistic-regression model was created with the use of baseline clinical and angiographic characteristics and procedure-related variables (including the method of revascularization -i.e., stenting or surgery) in order to identify independent predictors of the primary end point (event-free survival at one year).
Expectations about costs and cost effectiveness have been reported previously. 14 In that report, incremental cost-effectiveness ratios were expressed with the use of Fieller's approximation (with 95 percent confidence intervals). 23 
RESULTS
Characteristics and Treatment of the Patients
Between April 1997 and June 1998, 1205 patients at 67 participating centers were randomly assigned to undergo stent implantation (600 patients) or bypass surgery (605 patients). Table 1 presents their base-line demographic and angiographic characteristics. Five patients, one assigned to stenting and four assigned to surgery, did not undergo coronary revascularization and instead continued to receive pharmacologic treatment. The average interval between randomization and treatment was 27±39 days (range, 0 to 362) for *One patient in the stenting group had a myocardial infarction while on the waiting list for the procedure; in the surgery group, three patients died while on the waiting list, one patient had a cerebrovascular accident, and four patients had myocardial infarctions. CI denotes confidence interval, CABG coronary-artery bypass grafting, and PTCA percutaneous transluminal coronary angioplasty. †If a patient required repeated angioplasty and later required coronary-artery bypass grafting, only the worst event (CABG) was counted as an event. ‡If a patient required repeated angioplasty and later required coronary-artery bypass grafting, the total count for "CABG" and "PTCA" at 365 days would reflect both events, not just the worst that occurred, but the count for the general variable "Repeated revascularization" would reflect only one event. §In the stenting group, five cerebrovascular accidents were thrombotic, one was hemorrhagic, and the nature of the other four is unknown. In the surgery group, seven were thrombotic, one was hemorrhagic, and the nature of the other five is unknown. ¶P<0.001 by the Wilcoxon rank-sum test. 
Assessment of Revascularization and Postprocedural Enzyme Levels
Among the patients in the stenting group, a mean (±SD) of 2.8±1.0 lesions with stenosis of more than 50 percent of the luminal diameter were detected on the diagnostic angiogram, and 2.6±1.1 lesions had stents placed (89 percent) or were treated with balloon angioplasty alone (11 percent). However, in 15.2 percent of the patients in the stenting group, one or more of the target lesions did not receive the intended treatment, whereas in 10.2 percent of these patients procedures were performed that were not initially planned. In the surgery group, a mean of 2.8±1.0 lesions were found per patient, and a mean of 2.6±1.0 anastomoses were performed with the use of a mean of 2.5±0.7 conduits. In 4.5 percent of patients in this group, however, the intended surgical procedure was not performed. In 93 percent of the patients in the surgery group, at least one arterial conduit was used; in 95 percent of these patients, the left anterior descending artery was revascularized with an arterial conduit. In the stenting group, the average total length of the stents implanted was 47.5±21.8 mm per patient; 27 percent of the individual stents were longer than 15 mm. Bypass surgery required an average of 234±74 minutes, whereas stenting took an average of 98±52 minutes (P<0.001).
In the first 18 hours after the intervention, abnormal CK-MB levels were observed in 61 percent of the patients in the surgery group and 31 percent of the patients in the stenting group. Creatine kinase values more than five times the upper limit of normal were found in 12.6 percent of the patients in the surgery group and 6.2 percent of the patients in the stenting group (P<0.001).
Clinical Outcomes
In the stenting group, 40 percent of the major adverse events that occurred in the first 30 days after intervention were due to stent thrombosis. This complication occurred in 1.1 percent of the stented le- showed that an elevated level of CK-MB was the main predictor of outcome in the surgery group, whereas the presence of diabetes mellitus was the key predictor of outcome in the stenting group.
Quality of Life
Throughout the 12-month period of observation, more patients were free of angina after bypass surgery than after stenting ( Table 3 ). The data from the self-rated EuroQol questionnaire indicated a significantly better quality of life with stenting after 1 month, no difference after 6 months, and a slight difference in favor of surgery after 12 months. The difference at 12 months was attributable to significant differences in the ratings for "usual activity" and "anxiety or depression" and a nonsignificant difference in ratings for "mobility."
Costs and Cost Effectiveness
As Table 4 shows, the total costs of bypass surgery ($10,653) were significantly greater than those of stenting ($6,441) . The difference was due primarily to the differences in the duration of the procedures and the length of the hospital stay. The initial difference of $4,212 was later reduced because patients in the stenting group required more repeated revascularizations. Thus, the net difference in favor of stenting had decreased to $2,973 by one year. Had a policy of performing elective bypass surgery rather than angioplasty and stenting been applied to every patient enrolled in the trial, the additional costs at one year would have been approximately $21,329 per additional patient who survived event-free. sions but in 2.8 percent of the patients. The frequency of major adverse cardiac and cerebrovascular events and the number of patients in whom each type of event occurred are shown in Table 2 . One of these events occurred in 157 of the 600 patients assigned to stent implantation (26.2 percent) , as compared with 74 of the 605 patients assigned to bypass surgery (12.2 percent; relative risk, 2.14; 95 percent confidence interval, 1.66 to 2.75). Similar numbers of patients in the two groups were alive at one year and had not had a stroke or a myocardial infarction (90.7 percent in the stenting group and 91.2 percent in the surgery group; relative risk of death, stroke, or nonfatal myocardial infarction, 1.07; 95 percent confidence interval, 0.75 to 1.52). Of these patients, 16.8 percent in the stenting group and 3.5 percent in the surgery group underwent repeated revascularization (an absolute difference of 13.3 percent). Overall, 21.0 percent of the patients in the stenting group underwent additional revascularization, as compared with 3.8 percent of those in the surgery group (relative risk, 5.52; 95 percent confidence interval, 3.59 to 8.49). The different clinical outcomes are illustrated by the Kaplan-Meier estimates of event-free survival in the two original groups and among patients who survived for one year without a stroke or a myocardial infarction (Fig. 1) . The better outcome at one year for the patients in the surgery group was also reflected in a significantly higher proportion of patients without angina (90 percent after bypass surgery vs. 79 percent after stenting) and a lower rate of use of antianginal medications (Table 3) .
Multivariate Cox regression analysis in this trial *Plus-minus values are means ±SD. High scores on the EuroQol thermometer and the EuroQol summary indicate a good quality of life, whereas low scores on the other five items -mobility, self-care, usual activity, pain or discomfort, and anxiety or depression -reflect a favorable assessment of each individual component of the quality of life. †Respondents rate their overall health status using a 20-cm visual-analogue scale. This scale, which is similar to a thermometer, is marked 100 at the top (best imaginable state of health) and 0 at the bottom (worst imaginable state of health). ‡Information elicited on the five EuroQol domains is converted into a single EuroQol summary (range, 0 to 100) after the individual scores have been weighted to account for differences in the importance of the various domains to the patient. 
DISCUSSION
We found no significant difference between the two treatment groups in the combined rate of death, stroke, and myocardial infarction; a difference of 17.2 percentage points in the rate of repeated revascularization in favor of surgery; and lower costs (by $2,973) at 12 months in favor of coronary stenting. Our results present physicians with a dilemma. Angioplasty with stenting is less invasive than surgery and is associated with a faster recovery and a better quality of life one month after the intervention. Bypass surgery is associated with a lower incidence of angina, less need for antianginal medications, and fewer repeated interventions in the first year after the procedure. A decision to perform bypass surgery will probably cost approximately $3,000 more than a decision to perform angioplasty with stenting, but it may result in 14 additional patients with event-free survival per 100 treated patients, as suggested by the difference of 14 percentage points in event-free survival in our study. As compared with stenting, in other words, it would be necessary to perform bypass surgery in seven patients in order for one additional patient to survive for one year without adverse events (1.0÷0.14= 7.14); doing so would cost approximately $21,000 -an incremental cost-effectiveness ratio of $21,000 per additional patient who survives event-free. These figures are substantially more favorable than the costeffectiveness estimates for the use of abciximab in patients who are undergoing angioplasty 24 or for the use of primary balloon angioplasty in patients who have had a myocardial infarction. 25 The interval between randomization and treatment was approximately three times longer for the patients in the surgery group than for those in the stenting group, and eight major adverse cardiac events occurred in patients assigned to bypass surgery before they had undergone surgery, as compared with one such event *The costs per unit have been rounded in the calculation of the average. CCU denotes coronary care unit, ICU intensive care unit, PTCA percutaneous transluminal coronary angioplasty, and CABG coronary-artery bypass grafting. †P values were calculated with use of the Mann-Whitney rank-sum test. ‡Intraoperative hardware includes guiding catheters, guide wires, balloons, stents, atherectomy devices and laser catheters, Doppler and intravascular catheters, cardiopulmonary support and intra-aortic balloon-pump catheters, and endarterectomy devices. Abciximab, as an adjunctive intraoperative drug, was administered to 18 patients in the stenting group. §The costs for either a target or a nontarget vessel are included. in a patient assigned to stent implantation. These delays and events handicapped the late follow-up of the patients in the surgery group. There are reports that delays caused by waiting lists for cardiac surgery may pose risks. [26] [27] [28] The trial was initiated in April 1997, and one-year follow-up data were available in August 1999. Since practice evolves continuously, it is relevant to consider the differences between the techniques used in this study and newly developed techniques for coronary revascularization that may affect future practice, such as surgery without cardiopulmonary bypass and new, minimally invasive approaches. [29] [30] [31] [32] [33] [34] Conversely, the 2.8 percent stent thrombosis rate per patient might have been prevented by platelet glycoprotein IIb/IIIa receptor blockade 35 or use of a heparin-coated stent. 6, 36, 37 Furthermore, in 30 percent of the patients with stents, some release of CK-MB was documented; the use of glycoprotein IIb/IIIa inhibitors might have reduced this rate of enzyme release by 50 percent.
The observation that CK-MB enzyme release was the major predictor of clinical outcome in the surgery group, whereas the presence of diabetes mellitus was the key predictor in the stenting group, will further fuel the debate regarding the prognostic and pathophysiological significance of cardiac-enzyme release during surgical revascularization, but it corroborates the findings of the Bypass Angioplasty Revascularization Investigation with respect to the adverse clinical effects of diabetes in patients treated by percutaneous intervention. 38 Although surgery remains the most effective method of revascularization for multivessel disease, our findings tip the scales of cost effectiveness in favor of the percutaneous approach by demonstrating a substantial reduction in the difference between the outcomes of the procedures. However, "cost" must be defined from the perspective of society as a whole, and each patient's preference must be considered in making individual decisions. Although the percutaneous approach offers the same degree of protection against death and cardiac or cerebrovascular events as surgery and is generally perceived by patients as less invasive, the possible need for further revascularization after an initial percutaneous treatment has to be weighed by the patient and his or her physician in choosing an approach. We are indebted to Dr. Brian Firth, Paul Marshall, and Dr. Robert 
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